🌟 Join us at the Spatial Biology for Drug Development Summit to discover how AI spatial analysis enables data-driven decisions for next-gen therapeutics, including ADCs, multispecifics, and immuno-oncology (IO). Unlock the potential of AI Spatial Intelligence as it revolutionizes drug development and patient selection. In the lecture, our Director of Application Science, Jason Reeves will cover key insights such as: ✔️Identifying novel spatial biomarkers across imaging modalities for portfolio prioritization and positioning ✔️Modeling the bystander effect of ADC drug delivery within the tumor microenvironment for biomarker validation and patient selection ✔️Patient selection for prospective trials using AI-augmented biomarker scoring and quantification 📅 Wednesday, October 23, 2024 at 12:15 pm. Don’t miss it! Schedule a meeting with us today! https://bit.ly/3Ymu7Gw #SpatialBiology #DrugDevelopment #SpatialBiomarkers #DigitalPathology #PrecisionMedicine
Nucleai
Software Development
Chicago עוקבים, IL 16,449
The leading Spatial Biology Software Platform for Precision Medicine.
עלינו
Nucleai Brings AI-powered spatial biology technology to the forefront of precision medicine to improve drug development, clinical treatment decisions, and patient outcomes. Nucleai works with leading pharmaceutical companies, licensing its research platform for internal use, and collaborating in biomarkers discovery projects. Nucleai’s Atom: The leading Spatial Biology Platform for Precision Medicine.
- אתר אינטרנט
-
https://nucleai.ai/
קישור חיצוני עבור Nucleai
- תעשייה
- Software Development
- גודל החברה
- 51-200 עובדים
- משרדים ראשיים
- Chicago, IL
- סוג
- בבעלות פרטית
- הקמה
- 2018
- התמחויות
מיקומים
-
הראשי
Chicago, IL, US
עובדים ב- Nucleai
עדכונים
-
We’re proud to partner with the Spatial Biology for Drug Development Summit in Boston next month. Meet us there to learn how our AI-driven spatial biomarker and diagnostics solutions are advancing next-gen therapies. Learn more: https://lnkd.in/gPX8tz5R #spatialbiology #spatialbiomarkers #drugdevelopment #diagnostics
-
Proud to be part of Israel’s healthtech ecosystem, breaking new ground and improving patient care with AI innovation! #healthtech #AI #biotech
Explore how Israel’s AI-powered biotech sector is driving innovation and resilience in 2024. This update highlights key advancements in AI-driven healthcare, major investments, and new startups harnessing AI to transform drug discovery, clinical trials, and biological research. Whether you’re an investor, entrepreneur, or just curious about the future of healthcare, explore what makes Israel a key player in global biotech advancements. CytoReason, Nucleai, AION Labs, CombinAble.AI, TenAces Biosciences, QuantHealth, Converge Bio, Biolojic Design, Ltd.
-
We're boldly stepping into health's future at HLTH USA 2024! Meet our CEO and Co-founder, Avi Veidman to discover how Nucleai’s AI-driven spatial biomarkers and diagnostics are shaping next-gen therapies and the future of healthcare. Connect with us there! https://hubs.li/Q02QWDgX0 #BeBold #biotech #healthtech #innovation #AI #digitalpathology #AIpathology #spatialbiomarkers #diagnostics #CDx
-
Our recent collaboration with Dr. Arutha Kulasinghe, showcased at #WCLC24, highlights how AI-driven spatial analysis is enhancing biomarker insights, paving the way for developing predictive biomarkers for response to immunotherapy. We’re excited about the impact of this research and the future discoveries ahead! Learn more and download the full presentation! https://hubs.li/Q02QQHNF0 #spatialbiomarkers #AIpathology #DigitalPathology #PrecisionMedicine #Immunotherapy #LungCancer
-
As #ESMO24 wraps up, we’re excited to share insights from our latest head and neck study in collaboration with Gilead Sciences. The study reveals key differences between HPV+ and HPV- patients, highlighting the role of AI-powered spatial biomarkers in guiding therapy decisions. Missed our poster presentation? Download it here to explore the full findings.➡️https://lnkd.in/ghAiwg8H #ESMO2024 #SpatialBiomarkers #Biomarkers #DigitalPathology #AIPathology
-
Missed the presentation at #WCLC24? You can still catch up! 📄 The collaborative study, led by Dr. Arutha Kulasinghe, has uncovered a metabolic signature in tumor cells linked to immunotherapy resistance and survival in lung cancer patients. Discover how #AIPathology and #SpatialBiomarkers are driving the future of cancer care. Download the full presentation now! 🚀 👉 https://hubs.li/Q02P_f570 #WCLC2024 #LungCancer #NSCLC #biomarkers #DigitalPathology #Immunotherapy #PrecisionMedicine Ettai Markovits
-
Wrapping up another great day at ESMO - European Society for Medical Oncology Congress! Ettai Markovits, Ken Bloom, and Abhishek Aggarwal from Gilead Sciences were on hand to discuss the latest results from our head and neck study, revealing key spatial differences between HPV+ and HPV- patients that could serve as predictive biomarkers for therapy. Did you catch our poster? Meet us to learn more! https://hubs.li/Q02PVrnM0 #ESMO24 #SpatialBiomarkers #AIPathology #DigitalPathology #biomarkers #PrecisionMedicine
-
The Nucleai team is heading to Barcelona this weekend for the ESMO - European Society for Medical Oncology Congress. Meet our Head of Pathology, Ken Bloom, and Director of Biomedical Research, Ettai Markovits, to explore how AI spatial biomarkers and diagnostics are powering next-gen therapies. Book a meeting here ➡️https://hubs.li/Q02PHkjv0 And be sure to join us for our poster session on Saturday, Sept 14, where we’ll be presenting our latest findings in collaboration with Gilead Sciences. 📍 Poster #916P - Deep spatial profiling of head and neck squamous cell carcinoma offers insights into the tumor microenvironment of hpv-stratified patients #ESMO #SpatialBiomarkers #AIPathology #biomarker #DigitalPathology #ESMO24